U.S. Food and Drug Administration Protecting and Promoting *Your* Health

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

f f Share (https://www.facebook.com/sharer/sharer.php?
U=http://www.accessdata.fda.gov/scripts/cder/ob/results product.cfm?appl type=n&appl no=203971)

▼ TWEET (HTTPS://TWITTER.COM/INTENT/TWEET/?TEXT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS&URL=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/RESULTS PRODUCT.CFM?APPL TYPE=N&APPL NO=203971)

<u>+</u>

■ EMAIL (MAILTO:?SUBJECT=ORANGE BOOK: APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS&BODY=HTTP://WWW.ACCESSDATA.FDA.GOV/SCRIPTS/CDER/OB/RESULTS_PRODUCT.CFM?APPL_TYPE=N&APPL_NO=203971)

Marketing Status: Prescription

Home (default.cfm?resetfields=1) | Back to Search Results

Product Details for NDA 203971

XOFIGO (RADIUM RA-223 DICHLORIDE) 162mCi/6ML (27mCi/ML)

Active Ingredient: RADIUM RA-223 DICHLORIDE

Proprietary Name: XOFIGO

Dosage Form; Route of Administration: SOLUTION; INTRAVENOUS

Strength: 162mCi/6ML (27mCi/ML)

Reference Listed Drug: Yes

TE Code:

Application Number: N203971

Product Number: 001

Approval Date: May 15, 2013

Applicant Holder Full Name: BAYER HEALTHCARE PHARMACEUTICALS INC

Marketing Status: Prescription

Patent and Exclusivity Information (patent_info.cfm?

Product No=001&Appl No=203971&Appl type=N)

